Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 9 for:    spinal cord injury invivo
Previous Study | Return to List | Next Study

The INSPIRE Study: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by InVivo Therapeutics
Information provided by (Responsible Party):
InVivo Therapeutics Identifier:
First received: May 1, 2014
Last updated: April 10, 2017
Last verified: April 2017
  • To evaluate whether the Scaffold is safe and demonstrates probable benefit for the treatment of complete T2-T12/L1 spinal cord injury .
  • This is a Humanitarian Device Exemption (HDE) Probable Benefit Study to demonstrate safety and probable benefit in support of future studies and an HDE application with subsequent approval.

Condition Intervention Phase
Traumatic Thoracic Acute Spinal Cord Injury
Device: Neuro-Spinal Scaffold
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects With Complete Thoracic AIS A Spinal Cord Injury

Resource links provided by NLM:

Further study details as provided by InVivo Therapeutics:

Primary Outcome Measures:
  • Proportion of subjects with improvement in AIS grade of one or more levels [ Time Frame: 6 months ]
    A preset objective performance criterion (OPC) based upon this proportion will be used as the primary measure of success for this study.

Secondary Outcome Measures:
  • Proportion of subjects with improvement in motor scores [ Time Frame: 6 months ]
  • Proportion of subjects with improvement in sensory scores [ Time Frame: 6 months ]
  • Proportion of subjects with improvement in hip abduction/adduction or great toe flexion/extension [ Time Frame: 6 months ]
  • Proportion of subjects with improvement in bowel function [ Time Frame: 6 months ]
  • Proportion of subjects with improvement in bladder function [ Time Frame: 6 months ]
  • Proportion of subjects with improvement in SCIM III [ Time Frame: 6 months ]
  • Proportion of subjects with improvement in QLI-SCI III [ Time Frame: 6 months ]
  • Proportion of subjects with decreased pain [ Time Frame: 6 months ]
  • Incidence of all Adverse Device Effects of any kind/seriousness. [ Time Frame: 6 months ]

Estimated Enrollment: 20
Study Start Date: April 2014
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Neuro-Spinal Scaffold Device: Neuro-Spinal Scaffold


Ages Eligible for Study:   16 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Aged 16 - 70 years
  • AIS A traumatic spinal cord injury at neurological spinal cord level T2-T12/L1
  • Recent injury (must receive Scaffold within 96 hours from injury)
  • Non-penetrating contusion injury no less than approximately 4 mm diameter by MRI

Key Exclusion Criteria:

  • Incomplete spinal cord injury (AIS B, C, D, E)
  • Terminally ill
  • Spinal cord injury associated with traumatic brain injury
  • Subject on long term mechanical ventilation
  • Penetrating injuries
  • Radiographic or visual evidence of parenchymal dissociation or anatomic transection where the contusion completely bridges a full cross-section of the spinal cord
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02138110

Contact: Kristin Neff 617-863-5581
Contact: Juno Kim 617-863-5556

  Show 31 Study Locations
Sponsors and Collaborators
InVivo Therapeutics
Study Director: Lou Vaickus, MD InVivo Therapeutics
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: InVivo Therapeutics Identifier: NCT02138110     History of Changes
Other Study ID Numbers: InVivo-100-101
Study First Received: May 1, 2014
Last Updated: April 10, 2017

Keywords provided by InVivo Therapeutics:
Spinal Cord Injury (SCI)
Complete (AIS A) Traumatic Acute Spinal Cord Injury

Additional relevant MeSH terms:
Wounds and Injuries
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System processed this record on April 24, 2017